The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Short-term Risk of Death After Treatment With Nesiritide for Decompensated Heart Failure: A Pooled Analysis of Randomized Controlled Trials
Abstract
CONTEXT: Nesiritide improves symptoms in patients with acutely decompensated heart failure compared with placebo and appears to be safer than dobutamine. Its short-term safety relative to standard diuretic and vasodilator therapies is less clear. OBJECTIVE: To investigate the safety of nesiritide relative to noninotrope-based control therapies, primarily consisting of diuretics or vasodilators. DATA SOURCES: Primary reports of completed clinical trials as of December 2004 were obtained from the US Food and Drug Administration (FDA), the study sponsor (Scios Inc), a PubMed literature search using the terms nesiritide, clinical trials, and humans, and a manual search of annual meetings of 3 heart associations. STUDY SELECTION: Of 12 randomized controlled trials evaluating nesiritide, 3 met all inclusion criteria: randomized double-blind study of patients with acutely decompensated heart failure, therapy administered as single infusion (> or =6 hours), inotrope not mandated as control, and reported 30-day mortality. DATA EXTRACTION: Data were extracted from FDA and sponsor documents and corroborated with published articles when available. Thirty-day survival was assessed by meta-analysis using a fixed-effects model and time-dependent risk by Kaplan-Meier analysis with Cox proportional hazards regression modeling. Where deaths were described within a range of days after treatment, an extreme assumption was made favoring nesiritide over control therapy, an approach relevant to the time-dependent analyses. DATA SYNTHESIS: In the 3 trials, 485 patients were randomized to nesiritide and 377 to control therapy. Death within 30 days tended to occur more often among patients randomized to nesiritide therapy (35 [7.2%] of 485 vs 15 [4.0%] of 377 patients; risk ratio from meta-analysis, 1.74; 95% confidence interval [CI], 0.97-3.12; P = .059; and hazard ratio after adjusting for study, 1.80; 95% CI, 0.98-3.31; P = .057). CONCLUSIONS: Compared with noninotrope-based control therapy, nesiritide may be associated with an increased risk of death after treatment for acutely decompensated heart failure. The possibility of an increased risk of death should be investigated in a large-scale, adequately powered, controlled trial before routine use of nesiritide for acutely decompensated heart failure.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Pfeffer, M. A., McMurray, J. J. V., Velazquez, E. J., Rouleau, J.-L., Køber, L., Maggioni, A. P., Solomon, S. D., Swedberg, K., Van de Werf, F., White, H., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa032292 · Cited by 2,471
Effect of Oral Milrinone on Mortality in Severe Chronic Heart Failure
Packer, M., Carver, J. R., Rodeheffer, R. J., Ivanhoe, R. J., DiBianco, R., Zeldis, S. M., Hendrix, G. H., Bommer, W. J., Elkayam, U., Kukin, M. L., et al. (1991) · New England Journal of Medicine · doi:10.1056/nejm199111213252103 · Cited by 2,225
The design and analysis of cohort studies
Breslow, N. E., & Day, N. E. (1987) · International Agency for Research on Cancer eBooks · Cited by 1,312
(2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00795-x · Cited by 980
Colucci, W. S., Elkayam, U., Horton, D. P., Abraham, W. T., Bourge, R. C., Johnson, A. D., Wagoner, L. E., Givertz, M. M., Liang, C.-S., Neibaur, M., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200007273430403 · Cited by 911
Sackner-Bernstein, J. D., Skopicki, H. A., & Aaronson, K. D. (2005) · Circulation · doi:10.1161/01.cir.0000159340.93220.e4 · Cited by 765
Self-citationTopol, E. J., Moliterno, D. J., Herrmann, H. C., Powers, E. R., Grines, C. L., Cohen, D. J., Cohen, E. A., Bertrand, M., Neumann, F.-J., Stone, G. W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200106213442502 · Cited by 677
Califf, R. M., Adams, K. F., McKenna, W. J., Gheorghiade, M., Uretsky, B. F., McNulty, S. E., Darius, H., Schulman, K., Zannad, F., Handberg-Thurmond, E., et al. (1997) · American Heart Journal · doi:10.1016/s0002-8703(97)70105-4 · Cited by 665
Packer, M., Califf, R. M., Konstam, M. A., Krum, H., McMurray, J. J., Rouleau, J.-L., & Swedberg, K. (2002) · Circulation · doi:10.1161/01.cir.0000029801.86489.50 · Cited by 621
A Dose-Dependent Increase in Mortality with Vesnarinone among Patients with Severe Heart Failure
Cohn, J. N., Goldstein, S. O., Greenberg, B. H., Lorell, B. H., Bourge, R. C., Jaski, B. E., Gottlieb, S. O., McGrew, F., DeMets, D. L., & White, B. G. (1998) · New England Journal of Medicine · doi:10.1056/nejm199812173392503 · Cited by 613
Failing the Public Health — Rofecoxib, Merck, and the FDA
Topol, E. J. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048286 · Cited by 599
Gottlieb, S. S., Abraham, W., Butler, J., Forman, D. E., Loh, E., Massie, B. M., O'Connor, C. M., Rich, M. W., Stevenson, L. W., Young, J., et al. (2002) · Journal of Cardiac Failure · doi:10.1054/jcaf.2002.125289 · Cited by 549
(2000) · New England Journal of Medicine · doi:10.1056/nejm200011163432019 · Cited by 526
Butler, J., Forman, D. E., Abraham, W. T., Gottlieb, S. S., Loh, E., Massie, B. M., O'Connor, C. M., Rich, M. W., Stevenson, L. W., Wang, Y., et al. (2004) · American Heart Journal · doi:10.1016/j.ahj.2003.08.012 · Cited by 470
Cohn, J. N., Pfeffer, M. A., Rouleau, J., Sharpe, N., Swedberg, K., Straub, M., Wiltse, C., Wright, T. J., & for the MOXCON Investigators (2003) · European Journal of Heart Failure · doi:10.1016/s1388-9842(03)00163-6 · Cited by 384
Krumholz, H. M., Chen, Y.-T., Vaccarino, V., Wang, Y., Radford, M. J., Bradford, W. D., & Horwitz, R. I. (2000) · The American Journal of Cardiology · doi:10.1016/s0002-9149(00)00705-0 · Cited by 379
Mills, R. M., LeJemtel, T. H., Horton, D. P., Liang, C.-S., Lang, R., Silver, M. A., Lui, C., & Chatterjee, K. (1999) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(99)00184-9 · Cited by 324
Smith, G. L., Vaccarino, V., Kosiborod, M., Lichtman, J. H., Cheng, S., & Krumholz, H. M. (2002) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(02)82070-8 · Cited by 277
Randomised study of effect of ibopamine on survival in patients with advanced severe heart failure
Hampton, Jr., van Veldhuisen, D., Kleber, F., Cowley, A., Ardia, A., Block, P., Cortina, A., Cserhalmi, L., Follath, F., Jensen, G., et al. (1997) · The Lancet · doi:10.1016/s0140-6736(96)10488-8 · Cited by 256
Lubsen, J., Just, H., Hjalmarsson, A. C., La Framboise, D., Remme, W. J., Heinrich-Nols, J., Dumont, J. M., & Seed, P. (1996) · Heart · doi:10.1136/hrt.76.3.223 · Cited by 209
Cannon, C. P. (2004) · Cited by 189
A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure
Cohn, J. N., & Tognoni, G. (2002) · ACC Current Journal Review · doi:10.1016/s1062-1458(02)00651-7 · Cited by 149
Pfeffer, M. A., McMurray, J. J. V., & Velazquez, E. J. (2004) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.12.039 · Cited by 147
Cowley, A., & Skene, A. M. (1994) · Heart · doi:10.1136/hrt.72.3.226 · Cited by 129
Meta-analysis and Epidemiologic Studies in Drug Development and Postmarketing Surveillance
Temple, R. (1999) · JAMA · doi:10.1001/jama.281.9.841 · Cited by 94
Moe, G. W. P. L., Rouleau, J. L., Charbonneau, L. L., et al. (2000) · American Heart Journal · doi:10.1016/s0002-8703(00)90035-8 · Cited by 42
Cited by
2013 ACCF/AHA Guideline for the Management of Heart Failure
Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., Fonarow, G. C., Geraci, S. A., Horwich, T., Januzzi, J. L., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.05.019 · Cited by 12,536
2005 WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2009) · Circulation · doi:10.1161/circulationaha.109.192065 · Cited by 3,720
Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1)
Kellum, J. A., Lameire, N., & for the KDIGO AKI Guideline Work Group (2013) · Critical Care · doi:10.1186/cc11454 · Cited by 2,827
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
WRITING COMMITTEE MEMBERS, Hunt, S. A., Abraham, W. T., Chin, M. H., Feldman, A. M., Francis, G. S., Ganiats, T. G., Jessup, M., Konstam, M. A., Mancini, D. M., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.167586 · Cited by 2,251
Metadata
- Authors
- Sackner-Bernstein, J. D., Kowalski, M., Fox, M., & Aaronson, K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2005-04-20
- Volume
- 293
- Issue
- 15
- Pages
- 1900-5
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1988232724
- Cited by
- 693
- References
- 27
- FWCI
- 58.76
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.